Scholarlink

<p><i>Pseudomonas aeruginosa</i> is a pathogen responsible for healthcare-associated infections, and the emergence of carbapenem-resistant strains (CRPA) poses significant clinical challenges. Phage therapy is increasingly recognized as a promising strategy against drug-resistant bacteria. This study aimed to identify a phage capable of effectively lysing CRPA. Using CRPA clinical isolates (PA19N) as hosts, phages were isolated and purified from water samples via the double-layer agar plate assay. A <i>P. aeruginosa</i> phage, designated Henuyfy19N, was successfully isolated. Transmission electron microscopy revealed that it possesses a head with diameter of approximately 87.94 ± 1.32&#xa0;nm and a tail length of about 130.25 ± 3.65&#xa0;nm, and it forms plaques with clear, distinct margins. The phage exhibited an optimal multiplicity of infection (MOI) of 0.1 against PA19N, with a latent period of 10&#xa0;min, and a rise period of 30&#xa0;min. It demonstrated strong stability under various temperature and pH conditions but was sensitive to UV irradiation. Whole-genome sequencing showed that the phage has a 93,413&#xa0;bp linear dsDNA genome with a G + C content of 49.42%, containing 161 ORFs and 16 tRNAs; no known virulence or antibiotic resistance genes were detected. Functional annotation predicted genes involved in structural proteins, DNA replication/packaging, and lysis. In vitro, Henuyfy19N effectively inhibited PA19N growth, reduced viable bacterial counts, and exhibited anti-biofilm activity by both disrupting and preventing biofilm formation. In <i>Galleria mellonella</i> larvae and a mouse infection model, the phage demonstrated therapeutic efficacy against PA19N infections. These findings establish Henuyfy19N as a safe, stable, and effective candidate for the treatment of CRPA infection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characterization of phage Henuyfy19N against Pseudomonas aeruginosa and its efficacy in animal models

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Xin Wang,
  • Xinwei Zhang,
  • Dong Liu,
  • Jiaqi He,
  • Yingge Mao,
  • Qiaolian Zhao,
  • Zhigang Liu,
  • Xiaoquan Li,
  • Fang Wang,
  • Li Wang,
  • Qiming Li

摘要

Pseudomonas aeruginosa is a pathogen responsible for healthcare-associated infections, and the emergence of carbapenem-resistant strains (CRPA) poses significant clinical challenges. Phage therapy is increasingly recognized as a promising strategy against drug-resistant bacteria. This study aimed to identify a phage capable of effectively lysing CRPA. Using CRPA clinical isolates (PA19N) as hosts, phages were isolated and purified from water samples via the double-layer agar plate assay. A P. aeruginosa phage, designated Henuyfy19N, was successfully isolated. Transmission electron microscopy revealed that it possesses a head with diameter of approximately 87.94 ± 1.32 nm and a tail length of about 130.25 ± 3.65 nm, and it forms plaques with clear, distinct margins. The phage exhibited an optimal multiplicity of infection (MOI) of 0.1 against PA19N, with a latent period of 10 min, and a rise period of 30 min. It demonstrated strong stability under various temperature and pH conditions but was sensitive to UV irradiation. Whole-genome sequencing showed that the phage has a 93,413 bp linear dsDNA genome with a G + C content of 49.42%, containing 161 ORFs and 16 tRNAs; no known virulence or antibiotic resistance genes were detected. Functional annotation predicted genes involved in structural proteins, DNA replication/packaging, and lysis. In vitro, Henuyfy19N effectively inhibited PA19N growth, reduced viable bacterial counts, and exhibited anti-biofilm activity by both disrupting and preventing biofilm formation. In Galleria mellonella larvae and a mouse infection model, the phage demonstrated therapeutic efficacy against PA19N infections. These findings establish Henuyfy19N as a safe, stable, and effective candidate for the treatment of CRPA infection.